Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway
Authors
Keywords
Advanced gastric cancer, S-1, Leucovorin, Pharmacogenetic
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 79, Issue 1, Pages 69-79
Publisher
Springer Nature
Online
2016-12-02
DOI
10.1007/s00280-016-3209-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ramdomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study
- (2017) M. Jin et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): The START trial.
- (2017) Y. H. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial
- (2016) Shuichi Hironaka et al. LANCET ONCOLOGY
- Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer
- (2014) Y. Yamada et al. ANNALS OF ONCOLOGY
- S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis
- (2013) S Y Kim et al. BRITISH JOURNAL OF CANCER
- Impact of adding cisplatin to S-1 in elderly patients with advanced gastric cancer
- (2013) Tetsuji Terazawa et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- A compensatory effect upon splicing results in normal function of the CYP2A6*14 allele
- (2013) A. Joseph Bloom et al. Pharmacogenetics and Genomics
- Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor
- (2012) Yuehong Cui et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- S-1 for the treatment of gastrointestinal cancer
- (2012) Taroh Satoh et al. EXPERT OPINION ON PHARMACOTHERAPY
- A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of theUGT1A1andCYP2A6Polymorphisms on Clinical Activity
- (2012) Yoon Hee Choi et al. ONCOLOGY
- CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients
- (2011) S R Park et al. BRITISH JOURNAL OF CANCER
- Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)
- (2011) Hiroyuki Narahara et al. Gastric Cancer
- Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients
- (2010) Benjamin Chuah et al. CANCER SCIENCE
- Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial
- (2010) Jaffer A. Ajani et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer
- (2009) W. Koizumi et al. ANNALS OF ONCOLOGY
- Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
- (2009) Narikazu Boku et al. LANCET ONCOLOGY
- Association ofCYP2A6polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer
- (2009) Sun-Young Kong et al. PHARMACOGENOMICS
- Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer
- (2008) J Matsubara et al. BRITISH JOURNAL OF CANCER
- ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen
- (2008) J Wei et al. BRITISH JOURNAL OF CANCER
- CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1
- (2008) Ken-ichi Fujita et al. CANCER SCIENCE
- A Pilot Study of Oxaliplatin, Fluorouracil and Folinic Acid (FOLFOX-6) as First-Line Chemotherapy in Advanced or Recurrent Gastric Cancer
- (2008) Hui-Yan Luo et al. CHEMOTHERAPY
- Challenges in predicting the clinical outcome in S-1-based chemotherapy for gastric cancer patients
- (2008) Wataru Ichikawa et al. International Journal of Clinical Oncology
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
- (2008) Wasaburo Koizumi et al. LANCET ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started